<DOC>
	<DOCNO>NCT00785330</DOCNO>
	<brief_summary>DSHNHL R3 randomize clinical phase II study . The main objective estimate efficacy rituximab prophylactic medication prevention graft-versus-host-disease allogeneic peripheral stem cell transplantation patient high risk relapse aggressive B-cell Non-Hodgkin 's lymphoma . The important secondary objective estimate efficacy allogeneic stem cell transplantation clinical situation .</brief_summary>
	<brief_title>Allo-hNHL ( FluBuCy )</brief_title>
	<detailed_description>Patients age 18 65 year high- risk relapse histology proven aggressive Non-Hodgkin's-lymphoma eligible trial . Aggressive Non-Hodgkin 's lymphoma within study define : B-NHL : follicular lymphoma grade IIIÂ° lymphoblastic ( precursor ) lymphoma diffuse large cell cell lymphoma subtype variant include primary mediastinal lymphoma mantle cell lymphoma , blastic variant T-NHL : precursor T cell lymphoma peripheral T cell lymphoma , subtype variant angioimmunoblastic lymphoma anaplastic large cell lymphoma , subtype NK / T cell lymphoma High risk relapse progressive disease define ( ) primary progressive disease , ( b ) early relapse le 12 month remission duration least one risk factor accord international prognostic index ( IPI ) , ( c ) relapse progression high dose chemotherapy autologous transplantation , ( ) relapse progression lack autologous stem cell product . Patients type progression / relapse receive rituximab plus ifosfamide/carboplatin/etoposide ( R-ICE ) rituximab plus dexamethasone/high dose ARA-C/cisplatinum salvage therapy ( recommendation , part study medication ) . In patient biwth T cell lymphoma rituximab may replace alemtuzumab . If least stable disease achieve , patient definitely include . With inclusion , patient randomize receive either 375 mg/ m2 rituximab week 3 , 4 , 5 , 6 , 25 , 26 , 27 , 28 allogeneic stem cell transplantation additional medication . Conditioning transplantation consist Fludarabine 125 mg/m2 , Busulfan 12 mg/kg cyclophosphamide 120 mg/kg . Short-term ( day 1 day 28 ) mycophenolat mofetil tacrolimus use basis GVHD prophylaxis patient . Anti-thymocyte globulin use due centre decision patient unrelated donor</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>histology proven aggressive non Hodgkin 's lymphoma primary progressive disease early relapse le 12 month remission duration least one risk factor accord international prognostic index ( IPI relapse progression high dose chemotherapy autologous transplantation relapse progression lack autologous stem cell product . severe comorbidity impair organ function hypersensitivity use drug HIV positivity active hepatitis active malignant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>rituximab</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>diffuse large B cell lymphoma</keyword>
	<keyword>peripheral cell lymphoma</keyword>
	<keyword>graft-versus-host disease</keyword>
	<keyword>graft-versus-lymphoma effect</keyword>
	<keyword>allogeneic haematopoietic stem cell transplantation</keyword>
	<keyword>relapse primary progressive aggressive Non-Hodgkin 's lymphoma</keyword>
</DOC>